Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–142 of 142 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluzone High Dose Vaccine Clear all

Conditions: Influenza,Human, COVID-19
Interventions: Investigational Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza/COVID-19 Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2, Placebo; Biological · Combination Product · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 1,353 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 22
States / cities: Lake Forest, California • San Diego, California • Walnut Creek, California + 17 more

Conditions: Influenza, Gammopathy
Interventions: Fluzone; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4); Biological
Lead sponsor: Kaiser Permanente; Other
Eligibility: 65 Years and older
Enrollment: 1,500,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Oakland, California

Conditions: Influenza
Interventions: High-dose quadrivalent influenza virus vaccine, High-dose influenza virus vaccine, High-dose trivalent inactivated influenza vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 65 Years and older
Enrollment: 792 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Milford, Connecticut • Coral Gables, Florida • Wichita, Kansas + 6 more

Conditions: Influenza
Interventions: Inactivated Influenza A Vaccine A/H5N1, Placebo (IM), Placebo (ID); Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21, Saline - Day 21; Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 60 Years and older
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Raleigh, North Carolina • Rocky Mount, North Carolina • Statesville, North Carolina

Conditions: Elderly Immune System
Interventions: Flu Vaccine; Biological
Lead sponsor: Health Sciences North Research Institute; Other
Eligibility: 20 Years and older
Enrollment: 393 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Healthy
Interventions: Entolimod, Placebo, Influenza vaccine; Drug
Lead sponsor: Robert J. Pignolo; Other
Eligibility: 65 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Flu
Interventions: Fluad Vaccine, Fluzone HD Vaccine; Drug
Lead sponsor: David H. Canaday; Other
Eligibility: 65 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Influenza, Human
Interventions: ARCT-2304, Control vaccine younger adults, Control vaccine older adults, Placebo Vaccine; Biological · Other
Lead sponsor: Arcturus Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: La Mesa, California • San Bernardino, California • Longmont, Colorado + 1 more

Conditions: Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions: High-Dose Inactivated, Split-Virion Influenza Vaccine, Inactivated, Split-Virion Influenza Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 65 Years and older
Enrollment: 3,851 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 28
States / cities: Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 25 more

Conditions: Flu Vaccine
Interventions: Fluzone-High Dose Quadrivalent, Fluad, Flublock; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 65 Years to 125 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pain, Quality of Life, Injection Site Reaction, Adverse Drug Event
Interventions: FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX®; Biological
Lead sponsor: Duke University; Other
Eligibility: 65 Years and older
Enrollment: 267 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland • Durham, North Carolina

Conditions: Aging, Influenza Vaccine, Dendritic Cell, Vaccine Response
Interventions: Flu Vaccine (Year 1), Flu Vaccine (Year 2), Flu Vaccine (Year 3), Flu Vaccine (Year 4); Biological
Lead sponsor: The Jackson Laboratory; Other
Eligibility: 65 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
Interventions: Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine, Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 65 Years and older
Enrollment: 777 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 19
States / cities: Long Beach, California • Hollywood, Florida • Port Orange, Florida + 14 more

Conditions: Influenza Immunization
Interventions: Pandemic flu H5 mRNA vaccine, Placebo; Biological · Other
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 14
States / cities: La Mesa, California • DeLand, Florida • Lakeland, Florida + 11 more

Conditions: Healthy Volunteers, Influenza
Interventions: Flu H5 egg pandemic low dose vaccine, with adjuvant, Flu H5 Egg Pandemic medium dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, without adjuvant; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 640 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Tempe, Arizona • Rolling Hills Estates, California • San Diego, California + 12 more

Conditions: Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV), Bone Marrow Transplant (BMT), Dialysis
Interventions: Fluzone High Dose, Fluzone; Biological
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 5 Years to 35 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Influenza, Influenza-like Illness, Influenza, Human
Interventions: Influenza; Biological
Lead sponsor: Insight Therapeutics, LLC; Other
Eligibility: 65 Years and older
Enrollment: 598 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Avian Influenza, Bird Flu
Interventions: ND1.1, Placebo control; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Immunization; Infection|Transplantation Infection|Influenza, Influenza
Interventions: Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Heart Failure
Interventions: Influenza vaccine; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Higher Dose Intradermal H5 Vaccine

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

Immune Response to High-Dose vs. Standard Dose Influenza Vaccine

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care

Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

Senescent Immunity in Elders and Vaccine Responses (SILVER)

Simultaneous RZV and aIIV4 Vaccination

A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.

Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults

Adjuvanted Influenza Vaccination Year 2 Follow-On Survey

Safety Study of an Oral Vaccine to Prevent Avian Influenza

High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)

VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)